ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pelabresib

Also written as “Pelabresib” and “CPI-0610”.

In Novartis’s pipeline, BET inhibitor. Its studies are mostly in Primary Myelofibrosis · Hematologic Neoplasms · Lymphoma, Follicular · Lymphoma · Multiple Myeloma, led by 2 companies.

Drug pageCPI-0610: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 20, 202011 company-led studies, 7 open or runningAcquisition: Novartis acquired MorphoSys, May 2024Next primary completion: Mar 9, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis77 open or runningphase 3since Oct 20, 2020Oct 20, 2020Mar 9, 2028phase 1 · NCT07340190
Constellation Pharmaceuticalsits history only40 open or runningphase 2since Jun 5, 2014Sep 10, 2013none ahead
  • Named in Novartis’s own pipeline as DAK539 (pelabresib), phase 4, as of Nov 16, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2020Named pelabresibINNProposed as its International Nonproprietary Name in WHO's List 123 · before, CPI-0610
  2. Oct 20, 2020First study: phase 3 study in Primary MyelofibrosisFirst studyNCT04603495 · 430 enrolled · United States, Australia, Austria and more
  3. Jul 15, 2021MorphoSys acquired Constellation PharmaceuticalsAcquisitionWith it pelabresib (CPI-0610) · completed · MorphoSys (release filed with the SEC)
  4. May 2024Novartis acquired MorphoSysAcquisitionWith it pelabresib, which MorphoSys held · completed · Novartis
  5. May 2, 2024Phase 3 study in Hematologic NeoplasmsNCT06401356 · 50 planned · United States, Belgium, Italy and more
  6. Jan 6, 20263 phase 1 studiesNCT07340190, NCT07340138, NCT07422610
  7. Jan 15, 2026Phase 3 study in Primary MyelofibrosisNCT07357727 · 460 planned · United States, Argentina, Australia and more
  8. Aug 18, 2026Phase 1 study in Healthy ParticipantsNCT07783503 · 30 planned · United Kingdom
  9. Nov 12, 2026Primary completion moved from 2027-06-02 to 2029-12-31Date moved laterphase 3 · +31 months · NCT06401356

Ahead

  1. Nov 13, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07783503
  2. Mar 9, 2028Primary completion: phase 1 study in Advanced MalignanciesNCT07340190
  3. May 17, 2028Primary completion: phase 3 study in Primary MyelofibrosisNCT07357727
  4. Jun 28, 2028Primary completion: phase 1 study in Lymphoma, FollicularNCT07422610

TargetBeta

“BET inhibitor”the company's pipeline, read by Claude · source
“The hydrated form of pelabresib, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, pelabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby prevent…”NCIt, read by Claude
“Bromodomain and extra-terminal motif (BET) inhibitor”ChEMBL 37, by rule

Studies

All 7 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07783503Healthy Participants · United Kingdom1RecruitingNov 13, 202630
NCT07422610Lymphoma, Follicular · France, Italy, Spain and more1RecruitingJun 28, 202824
NCT07357727Primary Myelofibrosis · United States, Argentina, Australia and more3RecruitingMay 17, 2028460
NCT07340190Advanced Malignancies · France, Italy, Spain1RecruitingMar 9, 202824
NCT07340138Primary Myelofibrosis · Japan1Active, not recruitingJul 23, 20263
NCT06401356Hematologic Neoplasms · United States, Belgium, Italy and more3RecruitingDec 31, 202950
NCT04603495Primary Myelofibrosis · United States, Australia, Austria and more3Active, not recruitingAug 23, 2023430

How it is read

Names in the registry

  • “Pelabresib”, 7 entries
  • “pelabresib”, 2 entries
  • “CPI-0610”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.